Cite
Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial.
MLA
Livi, Lorenzo, et al. “Phase 2 Placebo-Controlled, Single-Blind Trial to Evaluate the Impact of Oral Ibandronate on Bone Mineral Density in Osteopenic Breast Cancer Patients Receiving Adjuvant Aromatase Inhibitors: 5-Year Results of the Single-Centre BONADIUV Trial.” European Journal of Cancer, vol. 108, Feb. 2019, pp. 100–10. EBSCOhost, https://doi.org/10.1016/j.ejca.2018.12.005.
APA
Livi, L., Scotti, V., Desideri, I., Saieva, C., Cecchini, S., Francolini, G., Becherini, C., Delli Paoli, C., Visani, L., Salvestrini, V., De Feo, M. L., Nori, J., Bernini, M., Sanchez, L., Orzalesi, L., Bianchi, S., & Meattini, I. (2019). Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial. European Journal of Cancer, 108, 100–110. https://doi.org/10.1016/j.ejca.2018.12.005
Chicago
Livi, Lorenzo, Vieri Scotti, Isacco Desideri, Calogero Saieva, Sara Cecchini, Giulio Francolini, Carlotta Becherini, et al. 2019. “Phase 2 Placebo-Controlled, Single-Blind Trial to Evaluate the Impact of Oral Ibandronate on Bone Mineral Density in Osteopenic Breast Cancer Patients Receiving Adjuvant Aromatase Inhibitors: 5-Year Results of the Single-Centre BONADIUV Trial.” European Journal of Cancer 108 (February): 100–110. doi:10.1016/j.ejca.2018.12.005.